Exclusive: CEO Says Despite Dendreon's Setbacks, This Is Only the Beginning of Immunotherapy Revolution
(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 08/11/11 -- In an exclusive interview, Dr. Manish Singh, President and CEO of ImmunoCellular Therapeutics (OTCBB: IMUC), shares his thoughts on recent headlines which have sent shockwaves through the entire biotechnology grouping on Wall Street.
Singh, a leading oncology field innovator, has positioned his firm as one of the leaders in the cancer vaccine space -- complete with products and technologies designed to harness the power of the patient's own immune system in order to not only fight but also improve the diagnosis of cancer.
With Dendreon share prices down significantly since reporting underwhelming second-quarter earnings and withdrawing 2011 revenue guidance last week, what impact do their recent setbacks have on the entire cancer immunotherapy space?
Does being a fast follower as opposed to a leader have its advantages? Can ImmunoCellular Therapeutics avoid some of the reimbursement issues Dendreon is facing -- and if so, how?
The full exclusive interview, including new details about the company's own leading drug candidate, ICT-107, is available now at:
In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:
News developments and live healthcare sector updates are available constantly via Twitter at:
About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com
Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.08.2011 - 16:21 Uhr
Sprache: Deutsch
News-ID 45320
Anzahl Zeichen: 0
contact information:
Town:
LOS ANGELES, CA
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Exclusive: CEO Says Despite Dendreon's Setbacks, This Is Only the Beginning of Immunotherapy Revolution"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
